Skip to main content
SpringerLink
Log in

Type 1 Diabetes Mellitus

  • Chapter
Challenging Cases in Endocrinology

Part of the book series: Contemporary Endocrinology ((COE))

  • 180 Accesses

Abstract

A 53-yr-old woman was diagnosed with type 1 diabetes mellitus in 1960 at the age of 15. She initially presented with weight loss, frequent urination, and an increased appetite. She has been treated with insulin since her initial diagnosis, having been started on a multiple daily injection (MDI) program in June 1992. Her diabetes was under good control with her glycosylated hemoglobin ranging from 7.4–8.6% (normal range 4–7%) after the MDI program was instituted.

Deceased

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Redberg RF. Coronary artery disease in women: understanding the diagnostic and management pitfalls. Medscape Women’s Health 1998; 3: 1.

    PubMed  CAS  Google Scholar 

  2. Galcera-Tomas J, Melgarejo-Moreno A, Garcia-Alberola A, Rodriguez-Garcia P, Lozano-Martinez J, Martinez-Hernandez J, Martinez-Fernandez S. Prognostic significance of diabetes in acute myocardial infarction. Are there differences linked to female gender ? Int J Card 1999; 69: 289–298.

    Article  CAS  Google Scholar 

  3. Lopez-Jimenez F, Goldman L, Johnson PA, Polanczyk CA, Cook EF, Fleishmann KE, Orav EJ, Lee TH. Effects of diabetes mellitus on the presentation and triage of patients with acute chest pain without known coronary artery disease. Am J Med 1998; 105: 500–505.

    Article  PubMed  CAS  Google Scholar 

  4. Nesto RW, Watson FS, Kowalchuk GJ, Zarich SW, Hill T, Lewis SM, Lane SE. Silent myocardial ischemia and infarction with peripheral vascular disease: Assessment by dipyridamole thallium-201 scintigraphy. Int J Card 1999; 69: 289–298.

    Article  Google Scholar 

  5. American Diabetes Association. Consensus Development Conference on the Diagnosis of Coronary Heart Disease in People with Diabetes: 10–11 Feb. 1998, Miami, FL. Diabetes Care 1998; 21: 1551–1559.

    Article  Google Scholar 

  6. American Diabetes Association Position Statement—Aspirin Therapy in Diabetes. ADA Clinical Practice Recommendations-2000. Diabetes Care 2000; 23: S61–S62.

    Google Scholar 

  7. Early Treatment Diabetic Retinopathy Study (ETDRS) Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus-ETDRS report 14. JAMA 1992; 68: 1292–1300.

    Google Scholar 

  8. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J of Med 1996; 335: 217–225.

    Article  Google Scholar 

  9. Kaplan RC, Heckbert SR, Weiss NS, Wahl PW, Smith NL, Newton KM, Psaty BM. Postmenopausal estrogens and risks of myocardial infarction in diabetic women. Diabetes Care 1998; 21: 1117–1121.

    Article  PubMed  CAS  Google Scholar 

  10. Walikonis JE, Lennon VA. Radioimmunoassay for glutamic acid decarboxylas (GAD65) autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus. Mayo Clinic Proc 1998; 73: 1161–1166.

    Article  CAS  Google Scholar 

  11. Solimena M, Folli F, Denis-Donini S, Comi GC, Pozza G, De Camilli P, Vicari AM. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type 1 diabetes mellitus. N Engl J Med 1998; 318: 1012–1020.

    Article  Google Scholar 

  12. Baekkeskov S, Aanstoot H-J, Christgau S, Reetz A, Solimena M, Cascalho M, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990; 347: 151–156.

    Article  PubMed  CAS  Google Scholar 

  13. Zimmet P, Turner R, McCarty D, Rowley M, Mackay I. Crucial points at diagnosis. Type 2 diabetes or slow type 1 diabetes. Diabetes Care 1999; 22: 59B - 64B.

    Google Scholar 

  14. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999; 48: 150–157.

    Article  PubMed  CAS  Google Scholar 

  15. Fukui M, Nakano K, Shigeta H, Yoshimori K, Fujii M, Kitagawa Y, et al. Antibodies to glutamic acid decarboxylase in Japanese diabetic patients with secondary failure of oral hypoglycaemic therapy. Diabetic Med 1997; 14: 148–152.

    Article  PubMed  CAS  Google Scholar 

  16. Bruno G, De Salvia A, Arcari R, Borra M, Grosso N, Carta Q, Trovati M, Veglio M, Pagano G. Clinical, immunological, and genetic heterogeneity of diabetes in an Italian population-based cohort of lean newly diagnosed patients aged 30–34 years. Piedmont Study Group for Diabetes Epidemiology. Diabetes Care 1999; 22: 50–55.

    Article  PubMed  CAS  Google Scholar 

  17. Turner R, Sratton I, Orton V, Manley S, Zimmet P, Mackay IR, et al. for UK Prospective Diabetes Study (UKPDS) Group. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 1997; 350: 1288–1293.

    Article  PubMed  CAS  Google Scholar 

  18. Yliharsila H, Tuomilehto J, Mackay IR, Zimmet P, Tuomilehto-Wolf E, Rowley MJ, Nissinen A. GAD Antibodies in elderly men in different categories of glucose tolerance. Diabetes Care 1999; 22: 996–997.

    Article  PubMed  CAS  Google Scholar 

  19. Ruige JB, Batstra MR, Aanstoot HJ, Bouter LM, Bruining GJ, de Neeling JN, Heine RJ. Low prevalence of antibodies to GAD65 in a 50- to 74-year-old general Dutch population. The Hoorn Study. Diabetes Care 1997; 20: 1108–1110.

    Article  PubMed  CAS  Google Scholar 

  20. Hatziagelaki E, Jaeger C, Maeser E, Bretzel RG, Federlin K. GAD 65 antibody but not ICA positivity in adult-onset diabetic patients is associated with early progression to clinical insulin dependency. Acta Diabetologica 1996; 33: 291–294.

    Article  PubMed  CAS  Google Scholar 

  21. Whittingham S, Byron SL, Tuomilehto J, Zimmet PZ, Myers MA, Vidgren G, et al. Autoantibodies associated with presymptomatic insulin-dependent diabetes mellitus in women. Diabetic Med 1997; 14: 678–685.

    Article  PubMed  CAS  Google Scholar 

  22. The Diabetes Control and Complications Trial Research Group. Effect of intensive insulin therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complication trial: a randomized control trial. Ann Intern Med 1998; 128: 517–523.

    Google Scholar 

  23. Littorin B, Sundkvist G, Hagopian W, Landin-Olsson M, Lernmark A, Ostman J, et al. Islet cell and glutamic acid decarboxylase antibodies present at diagnosis of diabetes predict the need for insulin treatment: a cohort study in young adults whose disease was initially labeled as type 2 or unclassifiable diabetes. Diabetes Care 1999; 22: 409–412.

    Article  PubMed  CAS  Google Scholar 

  24. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-Human insulin a rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396–402.

    Article  PubMed  CAS  Google Scholar 

  25. Jacobs MAJM, Keulen ETP, Kane K, Casteleijn S, Scheffer P, Deville W, Heine RJ. Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients: a comparison with human regular insulin during a three-meal test period. Diabetes Care 1997; 20: 1279–1286.

    Article  PubMed  CAS  Google Scholar 

  26. Colombel A, Murat A, Krempf M, Kuchly-Anton B, Charbonnel B. Improvement of blood glucose control in type 1 diabetic patients treated with lispro and multiple NPH injections. Diabetic Med 1999; 16: 319324.

    Google Scholar 

  27. Lougheed WD, Zinman B, Strack TR, Janis LJ, Weymouth AB, Bernstein EA, Korbas AM, Frank BH. Stability of insulin lispro in insulin infusion systems. Diabetes Care 1997; 20: 1061–1065.

    Article  PubMed  CAS  Google Scholar 

  28. Zinman B, Tildesley H, Chiasson J, Tsui E, Strack T. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997; 46: 440–443.

    Article  PubMed  CAS  Google Scholar 

  29. Melki V, Renard E, Lassmann-Vague V, Boivin S, Guerci B, Hanaire-Broutin H, et al. Improvement of HbAi c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care 1998; 21: 977–982.

    Article  PubMed  CAS  Google Scholar 

  30. Diabetes Control and Complications Research Group. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995; 18: 361–376.

    Article  Google Scholar 

  31. American Diabetes Association. Position statement—continuous subcutaneous insulin infusion. (Clinical Practice Recommendations 2000). Diabetes Care 2000; 23: S90.

    Google Scholar 

  32. Bode B, Steed DR, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Diabetes Care 1996; 19: 324–327.

    Article  PubMed  CAS  Google Scholar 

  33. United States Renal Data System: USRDS 1999 Annual Data Report. National Institute of Health, National Institutes of Diabetes and Digestive and Kidney Disease. Bethesda, MD. Apr. 1999.

    Google Scholar 

  34. Nelson RG, Knowler WC, Pettitt DJ, Bennett PH. Kidney diseases in diabetes. In: Harris MI, ed. Diabetes in America. 2nd ed., NIH Publ No. 95–1468, 1995, pp. 349–400.

    Google Scholar 

  35. Mauer M, Mogensen CE, Friedman EA, Diabetic nephropathy. In: Schrier RW, Gottschalk CW, ed. Diseases of the Kidney, 6th ed., vol. III, Little, Brown and Company, 1997, pp. 2019–2062.

    Google Scholar 

  36. Vora JP, Chattington PD, Ibrahim H. Clinical manifestations and natural history of diabetic nephropathy. In: Johnson RJ, Feehally J, ed. Comprehensive Clinical Nephrology, Mosby, London, UK, 2000, p. 6. 34. 3.

    Google Scholar 

  37. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 977–986.

    Article  Google Scholar 

  38. The Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type I diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381–389.

    Article  Google Scholar 

  39. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–1462.

    Article  PubMed  Google Scholar 

  40. Hebert LA, Bain RP, Verme D, Cattran D, Whittier FC, Tolchin N, Rohde RD, Lewis EJ, for the Collaborative Study Group. Remission of nephrotic range proteinuria in type I diabetes. Kidney Int 1994; 46: 1688–1693.

    Article  PubMed  Google Scholar 

  41. Wilmer WA, Hebert LA, Lewis EJ, Rohde RD, Whittier F, Cattran D, Levey AS, Lewis JB, Spitalewitz S, Blumenthal S, Bain RP. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the captopril study. Am J Kidney Dis 1999; 34: 308–314.

    Article  PubMed  CAS  Google Scholar 

  42. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–259.

    Article  Google Scholar 

  43. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition from ACEI to angiotensin II antagonists. Kidney Int 2000; 57: 1803–1817.

    Article  PubMed  CAS  Google Scholar 

  44. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1999; 54: 1283–1289.

    Article  Google Scholar 

  45. Amercan Diabetes Association. Position statement—standards of medical care for patients with diabetes mellitus. Diabetes Care 2000; 23: S32–S42.

    Google Scholar 

  46. American Diabetes Association: Position statement—diabetic nephropathy. Diabetes Care 2000; 23: S69–S72.

    Google Scholar 

  47. Molitch ME. Management of early diabetic nephropathy. Am J Med 1997; 102: 392–398.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. J. Woody Sistrunk MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruce R. Zimmerman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Center for Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Medical School, Chicago, IL, USA

    Mark E. Molitch MD

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Sistrunk, J.W., Zimmerman, B.R. (2002). Type 1 Diabetes Mellitus. In: Molitch, M.E. (eds) Challenging Cases in Endocrinology. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-277-7_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-277-7_16

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-249-0

  • Online ISBN: 978-1-59259-277-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation